PURE Bioscience Commences Testing of SDC in Produce
PURE Bioscience Commences Testing of SDC in Produce
Promising Results from Initial Tests with Deibel Labs Demonstrate SDC Potential as Food Processing Aid
SAN DIEGO--(BUSINESS WIRE)-- PURE Bioscience, Inc. (NASDAQ:PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has initiated testing of SDC-based formulas in direct food applications to determine efficacy in reducing food borne pathogens such as Listeria, E. coli and Salmonella. The new testing program builds on the earlier GRAS designation for SDC on food contact surfaces.
Based on promising results from initial tests at Deibel Laboratories, additional testing is underway at the University of Georgia using whole lettuce leaves. These and other planned tests are intended to optimize specific formulas for various intervention steps throughout a food processing program.
"Current chemistries are not providing the necessary overall protection to the food supply," said Charles T. Deibel, President and Chief Operating Officer, Deibel Laboratories. "SDC has the potential to make a dramatic impact in food processing and reduce overall contamination when implemented as a 360o farm-to-fork solution. SDC is ideally suited for direct food applications because it has broad spectrum efficacy, does not induce bacterial resistance, does not impart an odor or flavors to the food product, and is non-hazardous to food industry workers."
Michael L. Krall, President and CEO of PURE Bioscience, said, "We are seeking additional partners to continue development in produce as well as in other food processing segments. Our objective is to gather and present data necessary to gain appropriate regulatory clearances from the U.S. Food and Drug Administration and the Environmental Protection Agency, as well as to demonstrate SDC's efficacy to the agricultural market and food processing industry."
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
PURE Bioscience Investor Contact:
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com
KEYWORDS: United States North America California
INDUSTRY KEYWORDS:
